Up to 664 million euros! Ganneg Li Pharma signs a major overseas deal, stock hits the daily limit up, and the company responds.

On August 11, A-share pharmaceutical leader Gan Li Pharmaceutical saw its stock price rise against the market trend, hitting the daily price limit of 74.47 yuan per share by 9:40 AM, with funds locked on the price limit reaching 935 million yuan. Behind this unusual price movement may be the significant overseas licensing agreement announced by the company the previous evening. On the night of August 10, Gan Li Pharmaceutical announced that it had reached an exclusive licensing agreement with the international pharmaceutical giant A. Menarini International Licensing S.A., granting it the rights for marketing registration and commercialization of bufenogliflozin for overweight or obesity indications in 39 European countries and regions, including 27 EU member states and the UK. Regarding the stock price surge today and the details of the collaboration, a reporter called the investor relations department of Gan Li Pharmaceutical. The staff member responded that the company does not monitor secondary market fluctuations, but mentioned that the company had published a related overseas order announcement yesterday, expecting this order to have a certain impact on the companys profits for the year, although specifics will depend on how the agreement is executed. The company's net profit target for the fiscal year 2026 is 1.43 billion yuan, and they are currently working towards that goal. Specific performance will be detailed in future announcements. Reviewing the recent performance trends of Gan Li Pharmaceutical, phase pressures have already emerged. In this regard, the aforementioned staff member explained that the decline in first-quarter performance was caused by a combination of multiple factors: in terms of product structure, the high sales of the Mendong series are priced too low, which somewhat drags down overall profitability; on the production side, the transition between the companys Beijing and Shandong facilities affected capacity to some extent. Additionally, the adjustment of tax rates after the New Year also impacted the companys performance.